Valuation: Entrada Therapeutics, Inc.

Market Cap 248M 214M 200M 184M 345M 23.58B 351M 2.35B 920M 11.81B 930M 910M 39.08B P/E 2026 *
-1.65x
P/E 2027 * -1.87x
Enterprise Value 154M 133M 125M 114M 215M 14.68B 218M 1.46B 573M 7.35B 579M 566M 24.33B EV / Sales 2026 *
7.76x
EV / Sales 2027 * -2.05x
Free-Float
85.77%
Yield 2026 *
-
Yield 2027 * -
1 week+1.18%
Current month+1.18%
1 month-7.79%
3 months+0.29%
6 months-35.19%
Current year-33.17%
1 week 6.64
Extreme 6.64
7.97
1 month 5.72
Extreme 5.72
7.97
Current year 5.63
Extreme 5.63
16.45
1 year 4.93
Extreme 4.93
16.45
3 years 4.93
Extreme 4.93
21.79
5 years 4.93
Extreme 4.93
36.85
10 years 4.93
Extreme 4.93
36.85
Manager TitleAgeSince
Chief Executive Officer 50 01/08/2017
Director of Finance/CFO 47 01/11/2020
President 56 01/01/2024
Director TitleAgeSince
Director/Board Member 50 01/08/2017
Chairman 44 01/12/2020
Director/Board Member 67 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
7/31/26 A
5AM Venture Management LLC
SellCompany -1,718 0.0044%
7/31/26 A
5AM Venture Management LLC
SellCompany -1,718 0.0044%
3/1/26 A Free

Chairperson

160,261 0.4193%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+1.18%+29.62%-50.72% 248M
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+32.55%+72.63% 55.18B
-1.09%+32.96%+19.95%+499.45% 28.63B
+2.72%+3.41%-15.88%-4.90% 23.53B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
Average +3.46%+10.63%+50.58%+181.22% 26.38B
Weighted average by Cap. +4.35%+13.08%+49.46%+168.28%

Financials

2026 *2027 *
Net sales 19.88M 17.21M 16.06M 14.74M 27.72M 1.89B 28.14M 188M 73.86M 948M 74.66M 73.03M 3.14B 40.79M 35.3M 32.94M 30.24M 56.85M 3.88B 57.72M 387M 152M 1.95B 153M 150M 6.43B
Net income -175M -151M -141M -129M -243M -16.61B -247M -1.65B -648M -8.32B -655M -641M -27.53B -197M -171M -159M -146M -275M -18.79B -279M -1.87B -733M -9.42B -741M -725M -31.14B
Net Debt -93.49M -80.9M -75.51M -69.31M -130M -8.9B -132M -886M -347M -4.46B -351M -343M -14.75B -331M -287M -268M -246M -462M -31.55B -469M -3.14B -1.23B -15.81B -1.24B -1.22B -52.28B
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
07/08/26 $6.870 0.00% 458,069
06/08/26 $6.870 -2.69% 269,971
05/08/26 $7.060 -2.49% 591,549
04/08/26 $7.240 -0.28% 663,126
03/08/26 $7.260 +6.92% 500,498
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
6.870USD
Average target price
18.75USD
Spread / Average Target
+172.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRDA Stock